Premium
Phase I study of a humanized anti‐CD11/CD18 monoclonal antibody in multiple sclerosis
Author(s) -
Bowen James D.,
Petersdorf Stephen H.,
Richards Todd L.,
Maravilla Ken R.,
Dale David C.,
Price Tom H.,
John Tom P.St.,
Yu Albert S.
Publication year - 1998
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(98)90183-7
Subject(s) - medicine , pharmacokinetics , multiple sclerosis , immunogenicity , pharmacodynamics , pharmacology , adverse effect , cd18 , antibody , monoclonal antibody , gastroenterology , immunology
Objective To evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a humanized anti‐CD11/CD18 monoclonal antibody (Hu23F2G) in patients with multiple sclerosis. Methods In this phase I uncontrolled dose escalation study, patients (n = 24) with primary or secondary progressive multiple sclerosis received single intravenous infusions of Hu23F2G (0.01 to 4.0 mg/kg). Study parameters included safety, pharmacology, immunogenicity, and brain magnetic resonance imaging (MRI). Results Hu23F2G had few adverse effects, but 2 cases of urinary tract infection and 2 cases of gingivitis did occur. Transient leukocytosis developed in some subjects receiving ≥1.0 mg/kg. The pharmacokinetic response was nonlinear, with the area under the curve increasing out of proportion to the increase in dose. The mean terminal half‐life increased with dose and was 21.9 (SD, 12.8) hours at the 4.0 mg/kg dose. High saturation (>80%) of CD11/CD18 on circulating leukocytes was achieved with doses ≥0.2 mg/kg. The duration of high leukocyte saturation was dose‐dependent, persisting for more than a week at the 4.0 mg/kg dose. A marked decrease in leukocyte migration in response to cutaneous inflammation was observed. Antibodies against Hu23F2G were not detected. The neurologic examinations were stable except for 1 subject who had worsening weakness associated with an infection. No significant changes were noted on brain MRI scans. Conclusions Hu23F2G was tolerated at doses that achieved high degrees of leukocyte CD11/CD18 saturation with in vivo inhibition of leukocyte migration. Because this phase I study was not designed to determine the clinical efficacy of Hu23F2G, further studies are needed. Clinical Pharmacology & Therapeutics (1998) 64 , 339–346; doi: